文献速递新发突发、热带与寄生虫病细菌感染、耐药与抗菌药物

恶性疟原虫哌喹耐药替代标志物:表型-基因型关联研究

A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.
PubMed 文献 · Lancet Infect Dis · 2016-11-03

该研究在柬埔寨恶性疟患者中探索哌喹耐药的遗传标志物,发现plasmepsin 2-3基因簇扩增与体外哌喹耐药相关,多拷贝plasmepsin 2可预测双氢青蒿素-哌喹治疗失败,且其比例升高与治疗失败率增加高度相关。

要点

  • plasmepsin 2多拷贝是哌喹耐药的替代分子标志物,可预测双氢青蒿素-哌喹治疗失败。
  • 当多拷贝plasmepsin 2寄生虫比例超过22%时,第42天双氢青蒿素-哌喹疗效降至90%以下。

核心结论

  • 柬埔寨哌喹耐药与plasmepsin 2-3基因簇扩增强烈相关,多拷贝plasmepsin 2可作为追踪哌喹耐药的替代分子标志物。

研究设计与样本

  • 研究纳入2009-2015年柬埔寨接受双氢青蒿素-哌喹治疗并随访42天的恶性疟患者,对部分虫株进行体外和离体药物敏感性检测,并采用全基因组测序、qPCR、qRT-PCR和免疫印迹分析。

主要发现

  • 31株培养适应虫株的全基因组外显子测序显示,plasmepsin 2-plasmepsin 3基因簇扩增与体外哌喹耐药相关。
  • 134株离体虫株的哌喹生存试验特征与plasmepsin 2基因拷贝数相关。

临床怎么用

  • 可将plasmepsin 2多拷贝作为分子标志物监测哌喹耐药,并与K13和mdr1监测结合,为抗疟治疗和遏制政策提供及时信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Western Cambodia is the epicentre of Plasmodium falciparum multidrug resistance and is facing high rates of dihydroartemisinin-piperaquine treatment failures. Genetic tools to detect the multidrug-resistant parasites are needed. Artemisinin resistance can be tracked using the K13 molecular marker, but no marker exists for piperaquine resistance. We aimed to identify genetic markers of piperaquine resistance and study their association with dihydroartemisinin-piperaquine treatment failures. METHODS: We obtained blood samples from Cambodian patients infected with P falciparum and treated with dihydroartemisinin-piperaquine. Patients were followed up for 42 days during the years 2009-15. We established in-vitro and ex-vivo susceptibility profiles for a subset using piperaquine survival assays. We determined whole-genome sequences by Illumina paired-reads sequencing, copy number variations by qPCR, RNA concentrations by qRT-PCR, and protein concentrations by immunoblotting. Fisher's exact and non-parametric Wilcoxon rank-sum tests were used to identify significant differences in single-nucleotide polymorphisms or copy number variants, respectively, for differential distribution between piperaquine-resistant and piperaquine-sensitive parasite lines. FINDINGS: Whole-genome exon sequence analysis of 31 culture-adapted parasite lines associated amplification of the plasmepsin 2-plasmepsin 3 gene cluster with in-vitro piperaquine resistance. Ex-vivo piperaquine survival assay profiles of 134 isolates correlated with plasmepsin 2 gene copy number. In 725 patients treated with dihydroartemisinin-piperaquine, multicopy plasmepsin 2 in the sample collected before treatment was associated with an adjusted hazard ratio (aHR) for treatment failure of 20·4 (95% CI 9·1-45·5, p<0·0001). Multicopy plasmepsin 2 predicted dihydroartemisinin-piperaquine failures with 0·94 (95% CI 0·88-0·98) sensitivity and 0·77 (0·74-0·81) specificity. Analysis of samples collected across the country from 2002 to 2015 showed that the geographical and temporal increase of the proportion of multicopy plasmepsin 2 parasites was highly correlated with increasing dihydroartemisinin-piperaquine treatment failure rates (r=0·89 [95% CI 0·77-0·95], p<0·0001, Spearman's coefficient of rank correlation). Dihydroartemisinin-piperaquine efficacy at day 42 fell below 90% when the proportion of multicopy plasmepsin 2 parasites exceeded 22%. INTERPRETATION: Piperaquine resistance in Cambodia is strongly associated with amplification of plasmepsin 2-3, encoding haemoglobin-digesting proteases, regardless of the location. Multicopy plasmepsin 2 constitutes a surrogate molecular marker to track piperaquine resistance. A molecular toolkit combining plasmepsin 2 with K13 and mdr1 monitoring should provide timely information for antimalarial treatment and containment policies. FUNDING: Institut Pasteur in Cambodia, Institut Pasteur Paris, National Institutes of Health, WHO, Agence Nationale de la Recherche, Investissement d'Avenir programme, Laboratoire d'Excellence Integrative "Biology of Emerging Infectious Diseases".

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2016. PMID: 27818097. doi:10.1016/S1473-3099(16)30415-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。